Alternatives to hormone replacement therapy for menopause: An epidemiological evaluation;Les alternatives au traitement hormonal substitutif de la ménopause: Le point épidémiologique

Journal de Gynecologie Obstetrique et Biologie de la Reproduction

Volumn 33, Issue 3, 2004, Pages 195-209

  Ringa, V ^a  

^a HÔPITAL PAUL BROUSSE   (France)

Author keywords

Bisphosphonates; Menopause; Phytoestrogenes; Serms; Tibolone; Treatements

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; CONJUGATED ESTROGEN; ESTRADIOL; ESTROGEN; ETIDRONIC ACID; GENISTEIN; ISOFLAVONE; MEDROXYPROGESTERONE ACETATE; NORETHISTERONE; PARATHYROID HORMONE; PHYTOESTROGEN; PRASTERONE; RALOXIFENE; RISEDRONIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SOYBEAN PROTEIN; STRONTIUM; STRONTIUM RANELATE; TIBOLONE; UNCLASSIFIED DRUG; VITAMIN D;

BREAST CANCER; CANCER RISK; CLINICAL TRIAL; HIGH RISK POPULATION; HORMONE SUBSTITUTION; HOT FLUSH; HUMAN; LONG TERM CARE; MENOPAUSAL SYNDROME; MENOPAUSE; OSTEOLYSIS; OSTEOPOROSIS; REVIEW; RISK BENEFIT ANALYSIS; VASOMOTOR DISORDER;

EID: 2942737399     PISSN: 03682315     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0368-2315(04)96440-x     Document Type: Review

References (82)

1. Lock M. Symptom reporting at menopause: a review of cross-cultural findings. J Br Menopause Soc 2002; 8: 132-6.
2. Delanoe D. Les représentations de la ménopause: un enjeu des rapports sociaux d'âge et de sexe. Contracept Fertil Sex 1997; 25: 853-60.
3. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-33.
4. Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass M, Lane D et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA 2003; 289: 3243-53.
5. Shumaker SA, Legault C, Rapp SR, Thal L, Wallace RB, Ockene JK et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 2003; 289: 2651-62.
6. Rapp SR, Espeland MA, Shumaker SA, Henderson VW, Brunner RL, Manson JE et al. Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 2003; 289: 2663-72.
7. Pradhan AD, Manson JE, Rossouw JE, Siscovick DS, Mouton CP, Rifai N et al. Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women's Health Initiative observational study. JAMA 2002; 288: 980-7.
8. Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003; 362: 419-27.
9. Reginster JY. Traitement hormonal de la ménopause: traitement hormonal sustitutif classique ou tibolone? Effets sur l'os. J Gynecol Obstet Biol Reprod 2002; 31: 541-9.
10. Meunier PJ, Confavreux E, Tupinon I, Hardouin C, Delmas PD, Balena R. Prevention of early postmenopausal bone loss with cyclical etidronate therapy (a double-blind, placebo-controlled study and 1-year follow-up). J Clin Endocrinol Metab 1997; 82: 2784-91.
11. Herd RJ, Balena R, Blake GM, Ryan PJ, Fogelman I. The prevention of early postmenopausal bone loss by cyclical etidronate therapy: a 2-year, double-blind, placebo-controlled study. Am J Med 1997; 103: 92-9.
12. Storm T, Thamsborg G, Steiniche T, Genant HK, Sorensen OH. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 1990; 322: 1265-71.
13. Watts NB, Harris ST, Genant HK, Wasnich RD, Miller PD, Jackson RD et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 1990; 323: 73-9.
14. Harris ST, Watts NB, Jackson RD, Genant HK, Wasnich RD, Ross P et al. Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy. Am J Med 1993; 95: 557-67.
15. Rosen CJ. A tale of two worlds in prescribing etidronate for osteoporosis. Lancet 1997; 350: 1340.
16. Bone HG, Downs RW Jr, Tucci JR, Harris ST, Weinstein RS, Licata AA et al. Dose-response relationships for alendronate treatment in osteoporotic elderly women. Alendronate Elderly Osteoporosis Study Centers. J Clin Endocrinol Metab 1997; 82: 265-74.
17. Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998; 280: 2077-82.
18. Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 1995; 333: 1437-43.
19. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996; 348: 1535-41.
20. Pols HA, Felsenberg D, Hanley DA, Stepan J, Munoz-Torres M, Wilkin TJ et al. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Foxamax International Trial Study Group. Osteoporos Int 1999; 9: 461-8.
21. Hosking D, Chilvers CE, Christiansen C, Ravn P, Wasnich R, Ross P et al. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. N Engl J Med 1998; 338: 485-92.
22. Clemmesen B, Ravn P, Zegels B, Taquet AN, Christiansen C, Reginster JY. A 2-year phase II study with 1-year of follow-up of risedronate (NE- 58095) in postmenopausal osteoporosis. Osteoporos Int 1997; 7: 488-95.
23. Mortensen L, Charles P, Bekker PJ, Digennaro J, Johnston CC, Jr. Risedronate increases bone mass in an early postmenopausal population: two years of treatment plus one year of follow-up. J Clin Endocrinol Metab 1998; 83: 396-402.
24. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999; 282: 1344-52.
25. Reginster J, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 2000; 11: 83-91.
26. McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001; 344: 333-40.
27. Fukunaga M, Kushida K, Kishimoto H, Shiraki M, Taketani Y, Minaguchi H et al. A comparison of the effect of risedronate and etidronate on lumbar bone mineral density in Japanese patients with osteoporosis: a randomized controlled trial. Osteoporos Int 2002; 13: 971-9.
28. Cranney A, Waldegger L, Zytaruk N, Shea B, Weaver B, Papaioannou A et al. Risedronate for the prevention and treatment of postmenopausal osteoporosis. Cochrane Database Syst Rev 2003; 4: CD004523.
29. Chesnut CH 3rd, Silverman S, Andriano K, Genant H, Gimona A, Harris S et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med 2000; 109: 267-76.
30. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001; 344: 1434-41.
31. Meunier PJ, Slosman DO, Delmas PD, Sebert JL, Brandi ML, Albanese C et al. Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis - a 2-year randomized placebo controlled trial. J Clin Endocrinol Metab 2002; 87: 2060-6.
32. Reginster JY, Deroisy R, Dougados M, Jupsin I, Colette J, Roux C. Prevention of early postmenopausal bone loss by strontium ranelate: the randomized, two-year, double-masked, dose-ranging, placebo-controlled PREVOS trial. Osteoporos Int 2002; 13: 925-31.
33. Haguenauer D, Welch V, Shea B, Tugwell P, Adachi JD, Wells G. Fluoride for the treatment of postmenopausal osteoporotic fractures: a meta-analysis. Osteoporos Int 2000; 11: 727-38.
34. Gutteridge DH, Stewart GO, Prince RL, Price RI, Retallack RW, Dhaliwal SS et al. A randomized trial of sodium fluoride (60 mg) +/- estrogen in postmenopausal osteoporotic vertebral fractures: increased vertebral fractures and peripheral bone loss with sodium fluoride; concurrent estrogen prevents peripheral loss, but not vertebral fractures. Osteoporos Int 2002; 13: 158-70.
35. Cumming RG. Calcium intake and bone mass: a quantitative review of the evidence. Calcif Tissue Int 1990; 47: 194-201.
36. Looker AC, Harris TB, Madans JH, Sempos CT. Dietary calcium and hip fracture risk: the NHANES I Epidemiologic Follow-Up Study. Osteoporos Int 1993; 3: 177-84.
37. Chapuy MC, Arlot ME, Duboeuf F, Brun J, Crouzet B, Amaud S et al. Vitamine D3 and calcium to prevent hip fractures in elderly women. New Engl J Med 1992; 327: 1637-42.
38. Lips P, Graafmans WC, Ooms ME, Bezemze PD, Bouter LM. Vitamine D supplementation and fracture incidence in elderly persons. A randomised placebo-controlled trial. Ann Int Med 1996; 124: 400-6.
39. Haynes B, Dowsett M. Clinical pharmacology of selective estrogen receptor modulators. Drugs Aging 1999; 14: 323-36.
40. van den Brule FA, Kalbus MF, Gaspard UJ. Le Raloxifène: un modulateur sélectif du récepteur aux œstrogènes. J Gynecol Obstet Biol Reprod 1999; 28: 788-99.
41. Delmas PD, Bjarnason NH, Mitlak BH, Ravoux AC, Shah AS, Huster WJ et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997; 337: 1641-7.
42. Ettinger B, Black DM, Mitlak BH. Knickerbocker RK, Nickelsen T, Genant HK et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999; 282: 637-45.
43. Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 1999; 281: 2189-97.
44. Tsai KS, Yen ML, Pan HA, Wu MH, Cheng WC, Hsu SH et al. Raloxifene versus continuous combined estrogen/progestin therapy: densitometric and biochemical effects in healthy postmenopausal Taiwanese women. Osteoporos Int 2001; 12: 1020-5.
45. Barrett-Connor E, Grady D, Sashegyi A, Anderson PW, Cox DA, Hoszowski K et al. Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA 2002; 287: 847-57.
46. Yaffe K, Krueger K, Sarkar S, Grady D, Barrett-Connor E, Cox DA et al. Cognitive function in postmenopausal women treated with raloxifene. N Engl J Med 2001; 344: 1207-13.
47. Strickler R, Stovall DW, Merritt D, Shen W, Wong M, Silfen SL. Raloxifene and estrogen effects on quality of life in healthy postmenopausal women: a placebo-controlled randomized trial. Obstet Gynecol 2000; 96: 359-65.
48. Voss S, Quail D, Dawson A, Backstrom T, Aguas F, Erenus M et al. A randomised, double-blind trial comparing raloxifene HCl and continuous combined hormone replacement therapy in postmenopausal women: effects on compliance and quality of life. Br J Obstet Gynaecol 2002; 109: 874-85.
49. Albertazzi P, Di Micco R, Zanardi E. Tibolone: a review. Maturitas 1998; 30: 295-305.
50. Ross LA, Alder EM. Tibone and climateric symptoms. Maturitas 1995; 21: 127-36.
51. Siseles NO, Halperin H, Benencia HJ, Berg G, Pilnik S, Mesch V et al. A comparative study of two hormone replacement therapy regimens on safety and efficacy variables. Maturitas 1995; 21: 201-10.
52. Hammar M, Christau S, Nathorst-boos J, Rud T, Garre K. A double-blind, randomised trial comparing the effects of tibolone and continuous combined hormone replacement therapy in postmenopausal women with menopausal symptoms. Br J Obstet Gynaecol 1998; 105: 904-11.
53. Modelska K, Cummings S. Tibolone for postmenopausal women: systematic review of randomized trials. J Clin Endocrinol Metab 2002; 87: 16-23.
54. Nevinny-Stickel J. Double-blind cross-over study with Org OD 14 and placebo in postmenopausal patients. Arch Gynecol 1983; 234: 27-31.
55. Laan E, van Lunsen RH, Everaerd W. The effects of tibolone on vaginal blood flow, sexual desire and arousability in postmenopausal women. Climacteric 2001; 4: 28-41.
56. Kokcu A, Cetinkaya MB, Yanik F, Alper T, Malatyalioglu E. The comparison of effects of tibolone and conjugated estrogen-medroxyprogesterone acetate therapy on sexual performance in postmenopausal women. Maturitas 2000; 36: 75-80.
57. Meeuwsen IB, Samson MM, Duursma SA, Verhaar HJ. Muscle strength and tibolone: a randomised, double-blind, placebo-controlled trial. Br J Obstet Gynaecol 2002; 109: 77-84.
58. Genazzani AR, Benedek-Jaszmann LJ, Hart DM, Andolsek L, Kicovic PM, Tax L. Org OD 14 and the endometrium. Maturitas 1991; 13: 243-51.
59. Morris EP, Wilson PO, Robinson J, Rymer JM. Long term effects of tibolone on the genital tract in postmenopausal women. Br J Obstet Gynaecol 1999; 106: 954-9.
60. Berning B, van Kuijk C, Bennink HJ, Fauser BC. Absent correlation between vaginal bleeding and oestradiol levels or endometrial morphology during tibolone use in early postmenopausal women. Maturitas 2000; 35: 81-8.
61. Farish E, Barnes JF, Rolton HA, Spowart K, Fletcher CD, Hart DM. Effects of tibolone on lipoprotein(a) and HDL subfractions. Maturitas 1994; 20: 215-9.
62. Godsland IF. Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein (a) concentrations: analysis of studies published from 1974-2000. Fertil Steril 2001; 75: 898-915.
63. Bjarnason NH, Bjarnason K, Haarbo J, Bennink HJ, Christiansen C. Tibolone: influence on markers of cardiovascular disease. J Clin Endocrinol Metab 1997; 82: 1752-6.
64. Winkler UH, Altkemper R, Kwee B, Helmond FA, Coelingh Bennink HJ. Effects of tibolone and continuous combined hormone replacement therapy on parameters in the clotting cascade: a multicenter, double-blind, randomized study. Fertil Steril 2000; 74: 10-9.
65. Ginsburg J, Prelevic GM. Lack of significant hormonal effects and controlled trials of phyto-oestrogens. Lancet 2000; 355: 163-4.
66. Anderson JW, Johnstone BM, Cook-Newell ME. Meta-analysis of the effects of soy protein intake on serum lipids. N Engl J Med 1995; 333: 276-82.
67. Kronenberg F, Fugh-Berman A. Complementary and alternative medicine for menopausal symptoms: a review of randomized, controlled trials. Ann Intern Med 2002; 137: 805-13.
68. Murkies AL, Lombard C, Strauss BJ, Wilcox G, Burger HG, Morton MS. Dietary flour supplementation decreases postmenopausal hot flushes: effect of soy and wheat. Maturitas 1995; 21: 189-95.
69. Brzezinski A, Adlercreutz H, Shaoul R. Short-term effect of phytoestrogen-rich diet on postmenopausal women. Menopause 1997; 4: 89-94.
70. Dalais FS, Rice GE, Wahlqvist ML, Grehan M, Murkies AL, Medley G et al. Effects of dietary phytoestrogens in postmenopausal women. Climacteric 1998; 1: 124-9.
71. Albertazzi P, Pansini F, Bonaccorsi G, Zanotti L, Forini E, De Aloysio D. The effect of dietary soy supplementation on hot flushes. Obstet Gynecol 1998; 91: 6-11.
72. Washburn S, Burke GL, Morgan T, Anthony M. Effect of soy protein supplementation on serum lipoproteins, blood pressure, and menopausal symptoms in perimenopausal women. Menopause 1999; 6: 7-13.
73. Quella SK, Loprinzi CL, Barton DL, Knost JA, Sloan JA, LaVasseur BI et al. Evaluation of soy phytoestrogens for the treatment of hot flashes in breast cancer survivors: A North Central Cancer Treatment Group Trial. J Clin Oncol 2000; 18: 1068-74.
74. Scambia G, Mango D, Signorile PG, Anselmi Angeli RA, Palena C et al. Clinical effects of a standardized soy extract in postmenopausal women: a pilot study. Menopause 2000; 7: 105-11.
75. Upmalis DH, Lobo R, Bradley L, Warren M, Cone FL, Lamia CA. Vasomotor symptom relief by soy isoflavone extract tablets in postmenopausal women: a multicenter, double-blind, randomized, placebo- controlled study. Menopause 2000; 7: 236-42.
76. St Germain A, Peterson CT, Robinson JG, Alekel DL. Isoflavone-rich or isoflavone-poor soy protein does not reduce menopausal symptoms during 24 weeks of treatment. Menopause 2001; 8: 17-26.
77. Van Patten CL, Olivotto IA, Chambers GK, Gelmon KA, Hislop TG, Templeton E et al. Effect of soy phytoestrogens on hot flashes in postmenopausal women with breast cancer: a randomized, controlled clinical trial. J Clin Oncol 2002; 20: 1449-55.
78. van de Weijer PH, Barentsen R. Isoflavones from red clover (Promensil) significantly reduce menopausal hot flush symptoms compared with placebo. Maturitas 2002; 42: 187-93.
79. Han KK, Soares JM, Jr., Haidar MA, de Lima GR, Baracat EC. Benefits of soy isoflavone therapeutic regimen on menopausal symptoms. Obstet Gynecol 2002; 99: 389-94.
80. Nagata C, Takatsuka N, Kawakami N, Shimizu H. Soy product intake and hot flashes in Japanese women: results from a community-based prospective study. Am J Epidemiol 2001; 153: 790-3.
81. Somekawa Y, Chiguchi M, Ishibashi T, Aso T. Soy intake related to menopausal symptoms, serum lipids, and bone mineral density in postmenopausal Japanese women. Obstet Gynecol 2001; 97: 109-15.
82. Morabito N, Crisafulli A, Vergara C, Gaudio A, Lasco A, Frisina N et al. Effects of genistein and hormone-replacement therapy on bone loss in early postmenopausal women: a randomized double-blind placebo-controlled study. J Bone Miner Res 2002; 17: 1904-12.